The United Kingdom and the United States have finalized a significant bilateral deal that will keep no levies on UK medicine shipments being sold in the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has agreed to increase expenditure on pharmaceuticals through the National Health Service (NHS). This pledge ensures that duties on these crucial goods will be held at nothing for a duration of three years.
This development follows recent statements to hike import taxes on branded pharmaceutical products, with potential rates discussed up to 100%.
"This arrangement between the United Kingdom strengthens the global environment for cutting-edge drugs and introduces long-overdue fairness to American-British drug exports," a statement declared.
Trade Significance
Drugs represent one of the Britain's biggest export categories to the US, which is clearly the largest destination for leading companies like GSK and AstraZeneca.
Statistics indicate that in the year leading up to last September, the UK shipped medicines valued at over eleven billion pounds to the US. This amount represented nearly one-fifth of all goods exports in that timeframe.
"This deal secures work, boosts investment and paves the way for the UK to become a global hub for medical research," the Business and Trade Secretary commented.
Specific UK Commitments
The agreement involves several notable commitments from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new medicines to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a target to raise total public funding on medicines from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The amount pharmaceutical firms must return to the NHS to control costs will be capped at 15%. Previously, rebates topped 20%.
Recent Tensions
The deal follows a protracted row between the drug companies and the ministers over spending levels and regulatory access.
These tensions were heightened by assertions that US customers were paying a premium for the identical medicines than people in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been paused or scrapped, while multi-billion-dollar expansions have been announced toward American operations.
The Science Minister stated that the NHS had to increase expenditure on medicines, noting that its budget allocation on drugs had declined as a proportion of its total funding over the past decade.
